Dr. Charles Kunos is a Professor in the Department
of Radiation Oncology in the University of Miami Sylvester Comprehensive Cancer
Center (SCCC). He joined SCCC in 2023 and serves as the co-director of
radiopharmaceutical development initiative for adult and pediatric cancer
patients. He received his medical and doctorate degrees from Case Western
Reserve University School of Medicine in Cleveland, Ohio. He undertook
radiation oncology training at the National Cancer Institute (NCI)-designated
Case Comprehensive Cancer Center at University Hospitals of Cleveland. He was
formerly the NCI Gynecologic Oncology Group’s liaison for Radiation Medicine,
serving on multiple committees and task forces as well as serving as a Phase I
co-chair of the Developmental Therapeutics Committee between 2012 and 2015. His
clinical research interests involve development of a diverse anticancer drug
portfolio involving experimental therapeutic agents and radiopharmaceuticals
that manipulate DNA damage responses by themselves or in combination with other
treatments. He led NCI’s team that was granted Food & Drug Administration
Orphan Drug Designation and Fast Track Designation for triapine in combination
with cisplatin-radiation therapy for treatment of women with advanced stage
uterine cervix cancer.
Dr. Charles Kunos is a Professor in the Department
of Radiation Oncology in the University of Miami Sylvester Comprehensive Cancer
Center (SCCC). He joined SCCC in 2023 and serves as the co-director of
radiopharmaceutical development initiative for adult and pediatric cancer
patients. He received his medical and doctorate degrees from Case Western
Reserve University School of Medicine in Cleveland, Ohio. He undertook
radiation oncology training at the National Cancer Institute (NCI)-designated
Case Comprehensive Cancer Center at University Hospitals of Cleveland. He was
formerly the NCI Gynecologic Oncology Group’s liaison for Radiation Medicine,
serving on multiple committees and task forces as well as serving as a Phase I
co-chair of the Developmental Therapeutics Committee between 2012 and 2015. His
clinical research interests involve development of a diverse anticancer drug
portfolio involving experimental therapeutic agents and radiopharmaceuticals
that manipulate DNA damage responses by themselves or in combination with other
treatments. He led NCI’s team that was granted Food & Drug Administration
Orphan Drug Designation and Fast Track Designation for triapine in combination
with cisplatin-radiation therapy for treatment of women with advanced stage
uterine cervix cancer.